Liglinra

Linagliptin, the active ingredient in Liglinra, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Liglinra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Liglinra, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder.

- Type 2 diabetes mellitus (adult): improves overall glycaemic control as monotherapy or in combination with other antidiabetic agents. - Type 2 diabetes mellitus (adjunct): reduces HbA1c levels when added to diet and exercise. - Type 2 diabetes mellitus (renal safety): provides glucose lowering without dose adjustment in patients with renal impairment.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nasopharyngitis - Headache - Dizziness - Upper respiratory tract infection - Gastrointestinal discomfort - Back pain

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Bullous pemphigoid - Hepatic injury - Angioedema - Anaphylactic shock

When prescribing Liglinra, several safety considerations should be observed.

- Renal impairment: monitor renal function; linagliptin does not require dose adjustment but caution is advised. - Hepatic impairment: use with caution and monitor liver enzymes. - History of pancreatitis: avoid or use only if benefits outweigh risks. - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; monitor blood glucose. - Pregnancy and lactation: safety not established; prescribe only if clearly needed. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Linagliptin can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness. - Insulin secretagogues (e.g., sulfonylureas, meglitinides): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose control; monitor blood glucose. - ACE inhibitors or ARBs: monitor renal function when combined.